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A B S T R A C T
The harmonized Canadian Dementia Imaging Protocol (CDIP) has been developed to suit the needs of a number
of co-occurring Canadian studies collecting data on brain changes across adulthood and neurodegeneration. In
this study, we verify the impact of CDIP parameters compliance on total brain volume variance using 86 scans of
the same individual acquired on various scanners. Data included planned data collection acquired within the
Consortium pour l'identification précoce de la maladie Alzheimer - Québec (CIMA-Q) and Canadian Consortium
on Neurodegeneration in Aging (CCNA) studies, as well as opportunistic data collection from various protocols.
For images acquired from Philips scanners, lower variance in brain volumes were observed when the stated CDIP
resolution was set. For images acquired from GE scanners, lower variance in brain volumes were noticed when
TE/TR values were within 5% of the CDIP protocol, compared to values farther from that criteria. Together,
these results suggest that a harmonized protocol like the CDIP may help to reduce neuromorphometric mea-
surement variability in multi-centric studies.
1. Introduction
Quantitative methods to extract specific and sensitive biomarkers
from neuroimages (e.g. algorithms, software)(Frisoni et al., 2013) can
be shared to ensure that similar post-acquisition processing is per-
formed in a standardized fashion. However, there will be a large var-
iance in the data from laboratory to laboratory if one does not stan-
dardize beforehand the process of acquiring the imaging data. This is
especially true of longitudinal, multi-centric settings where the wide
array of models and vendors, on top of configuration changes
throughout the life cycle of these scanners, significantly affects per-
formance and data quality.
To counteract these effects, several initiatives have developed
standard operating procedures to minimize variability in neuroimage
acquisition. Within the context of aging and neurodegeneration, one of
the most well-known of such efforts was advanced by the Alzheimer's
Disease Neuroimaging Initiative (ADNI)(www.adni-info.org). It has
proposed comprehensive cognitive, behavioural, and especially neu-
roimaging procedures that have been harmonized and implemented
across> 55 sites in Canada and the U.S. (Jack Jr. et al., 2008).
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In Canada, a collection of studies centered on dementias started
acquiring data in the 2013–2016 timeframe and needed a common,
harmonized process for magnetic resonance imaging (MRI) data ac-
quisition that went beyond the ADNI standard of the time. Thus, a
group of physicists, physicians and research coordinators developed
what is referred to as the Canadian Dementia Imaging Protocol (CDIP;
www.cdip-pcid.ca)(Duchesne et al., 2019). The CDIP includes the fol-
lowing sequences: (a) an isotropic high-resolution 3D T1-weighted
(T1w) MRI; (b) an interleaved PD/T2-weighted MRI; (c) T2* and FLAIR
MRIs; (d) a 30+ directions diffusion MRI; and (e) a functional con-
nectivity, resting-state BOLD MRI. Parameters for each one of these
sequences were harmonized across three MRI vendors, namely General
Electric Healthcare (GE), Phillips Medical Systems (Philips), and Sie-
mens Healthcare (Siemens). Sites are said to be CDIP-compliant when
they follow a three-step process, namely qualification of the protocol,
on-going quality control using geometric and human phantom scans,
and on-going quality assurance during the study.
Yet while harmonization might be appealing in principle, the de-
monstration of its usefulness remains to be completed. Limited data
exists on the pre/post advantages of harmonizing acquisition para-
meters. This study clarifies some of this uncertainty by assessing the
effect of deviation from compliance to the CDIP T1w MRI protocol on
Table 1
Characteristics of scans.
Site Vendor Model Resolution (mm3) TE (msec) TR (msec) Flip angle TI (msec) Plane Number of scans
CDIP acquisitions
CAMH GE DISCOVERY MR750 1.00 2.94 6.7 11 400 Sagittal 1
Hamilton GE DISCOVERY MR750 1.00 3.18 8.2 11 400 Sagittal 1
PERFORM GE DISCOVERY MR750 1.00 2.98 6.9 11 400 Sagittal 2⁎
Seaman GE DISCOVERY MR750 1.00 3.08 7.5 11 400 Sagittal 1
GE DISCOVERY MR750 1.00 3.05 7.4 11 400 Sagittal 2
WCMI GE SIGNA Pioneer 0.88 3.16 7.4 12 450 Sagittal 2
CHUM Philips Achieva 1.00 3.30 7.3 9 ns Sagittal 2
Philips Ingenia 1.00 3.35 7.3 9 ns Sagittal 1
CHUS Philips Ingenia 1.00 3.30 7.3 9 ns Sagittal 3
Philips Ingenia 1.00 3.33 7.3 9 ns Sagittal 1
IRM Quebec Philips Achieva 1.00 3.14 6.9 9 ns Sagittal 1
Philips Achieva 1.00 3.33 7.3 9 ns Sagittal 2
Philips Achieva 1.00 3.31 7.3 9 ns Sagittal 2
Philips Achieva 1.00 3.36 7.4 9 ns Sagittal 2
Philips Achieva 1.00 3.34 7.4 9 ns Sagittal 1
Philips Achieva 1.00 3.35 7.4 9 ns Sagittal 1
Philips Achieva 1.00 3.30 7.3 9 ns Sagittal 1
UBC Philips Intera 1.00 3.28 7.3 9 ns Sagittal 1
Philips Intera 1.00 3.27 7.2 9 ns Sagittal 1
BIC Siemens TrioTim 1.00 2.98 2300.0 9 900 Sagittal 7
Siemens Prismafit 1.00 2.96 2300.0 9 900 Sagittal 3
SickKids Siemens Prismafit 1.00 2.98 2300.0 9 900 Sagittal 1
IUGM Siemens TrioTim 1.00 2.98 2300.0 9 900 Sagittal 7
Siemens Prismafit 1.00 2.96 2300.0 9 900 Sagittal 4
Siemens Prismafit 1.00 2.98 2300.0 9 900 Sagittal 2
IUSMD Siemens TrioTim 1.00 2.98 2300.0 9 900 Sagittal 5
Siemens Prismafit 1.00 2.98 2300.0 9 900 Sagittal 1
Ottawa Siemens TrioTim 1.00 2.98 2300.0 9 900 Sagittal 1
Peter S. Allen Siemens Prisma 1.00 2.98 2300.0 9 900 Sagittal 2
Queens Siemens TrioTim 1.00 1.97 2300.0 9 900 Sagittal 1
Robarts Siemens Prismafit 1.00 2.98 2300.0 9 900 Sagittal 2
RUH Siemens Skyra 1.00 2.98 2300.0 9 900 Sagittal 2
St. Michael's Siemens Skyra 1.00 2.98 2300.0 9 900 Sagittal 1
Sunnybrook Siemens Prisma 1.00 2.98 2300.0 9 900 Sagittal 1
York Siemens Prismafit 1.00 2.98 2300.0 9 900 Sagittal 1
CDIP total 69
Non-CDIP acquisitions
Philips Philips Ingenia CX 1.00 3.30 7.3 9 ns Sagittal 1
Philips Ingenia CX 0.22 5.57 11.8 8 ns Sagittal 2
IRM Quebec Philips Achieva 0.48 na na na ns Sagittal 2
Philips Achieva 0.48 na na na ns Axial 1
Philips Achieva 1.00 3.13 6.9 8 ns Sagittal 2
Philips Achieva 0.69 na na na ns Sagittal 1
Philips Achieva 0.48 na na na ns Sagittal 1
Philips Achieva 1.00 3.14 6.9 8 ns Sagittal 2
Siemens Siemens Prisma 1.00 2.98 2300.0 9 900 Sagittal 1
Siemens Prisma 0.58 3.08 2300.0 9 900 Sagittal 2
Siemens Skyra 1.00 2.96 2300.0 9 900 Sagittal 1
Siemens Skyra 0.58 3.08 2300.0 9 900 Sagittal 1
Non-CDIP total 17
BIC: McConnell Brain Imaging Centre. CAMH: The Centre for Addiction and Mental Health. CHUM: Centre hospitalier universitaire de Montreal. CHUS: Centre
hospitalier universitaire de Sherbrooke. IUSMD: Brain Imaging Center of the Institut universitaire en santé mentale Douglas. Hamilton: St-Joseph's Healthcare
Hamilton. SickKids: Hospital for Sick Children. IUGM: Institut universitaire de gériatrie de Montréal. Ottawa: The Ottawa Hospital Civic. PERFORM: Concordia
University Perform Centre. Peter S. Allen: Peter S. Allen MR Research Centre. Queens: Queens University. Robarts: Robarts Research Institute. RUH: Royal University
Hospital. Seaman: Seaman Family MR Research Centre. St. Michael's: St. Michael's Hospital. Sunnybrook: Sunnybrook Research Institute. ns: Not specified. TE: Echo
time. TI: Inversion time. TR: Repetition time. UBC: University of British Colombia. WCMI: West Coast Medical Imaging – Uptown. York: York MRI Facility. ⁎One scan
resolution is actually 0.999mm3.
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brain morphometry variance. Deviation from the CDIP was analyzed for
three key parameters (resolution, echo time and repetition time). Our
hypothesis was that increasing compliance to CDIP would lower
variability in morphometric brain measures, outside of the application
of any further specific image pre/post processing. A secondary objective
was to release publicly for unrestricted usage this unique dataset,
comprising nearly 100 T1w MRI scans of the same individual acquired
on various scanners over the course of a few years.
2. Materials and methods
2.1. Participant
A Single Individual volunteering for Multiple Observations across
the Network (SIMON) took part in this study (SIMON Dataset; http://
fcon_1000.projects.nitrc.org/indi/retro/SIMON.html SIMON is an am-
bidextrous male aged between 38 and 46 years old across the scans used
in the present study, and was free from known cognitive impairment,
neurological disease or psychiatric disorders. The volunteer provided
informed consent for all participating studies as well as the release of
the MR data.
2.2. Participating studies
Several organizations and projects have contributed to the ela-
boration of the CDIP protocol and the acquisition of SIMON data,
namely the Canadian Alliance for Healthy Hearts and Minds (Anand et al.,
2016)(cahhm.mcmaster.ca); the Consortium pour l'identification précoce
de la maladie d'Alzheimer – Québec (CIMA-Q)(www.cima-q.ca); the O2
study from the Consortium Québécois sur la Découverte du Médicament
(www.cqdm.org); the Medical Imaging Trials Network of Canada – C6
(clinicaltrials.gov/ct2/show/NCT02330510); and the Ontario Brain In-
stitute's Ontario Neurodegenerative Disease Research Initiative (Farhan
et al., 2017)(ondri.ca). CIMA-Q was founded in 2013 with a $2,500,000
grant from the Fonds d'Innovation Pfizer - Fond de Recherche Québec –
Santé sur la maladie d'Alzheimer et les maladies apparentées. The main
objective is to build a cohort of participants characterized in terms of
cognition, neuroimaging and clinical outcomes in order to acquire
biological samples allowing 1) to establish early diagnoses of Alzhei-
mer's disease, 2) to provide a well characterized cohort and 3) to
identify new therapeutic targets. The principal investigator and director
of CIMA-Q is Dr. Sylvie Belleville of the Centre de recherche de l'Institut
universitaire de gériatrie de Montréal, CIUSSS Centre-sud-de-l'Île-de-
Montréal. CIMA-Q represent a common effort of several researchers
from Québec affiliated with Université Laval, McGill University, Uni-
versité de Montréal, and Université de Sherbrooke. CIMA-Q recruited
350 cognitively healthy participants, with subjective cognitive impair-
ment, mild cognitive impairment, or Alzheimer's disease, between 2013
and 2016.
2.3. Participating centers
Most scans were acquired as part of three projects, namely the
CIMA-Q, the Canadian Consortium for Neurodegeneration of Aging
(CCNA), and courtesy scans at MR manufacturers. Scans were thus
obtained at 23 different sites (see also Table 1): The Centre for Addic-
tion and Mental Health (Toronto, Canada), St-Joseph's Healthcare Ha-
milton (Hamilton, Canada), the MRI unit of the PERFORM Center of
Concordia University (Montréal, Canada), the Seaman MRI Center of
the University of Calgary (Calgary, Canada), West Coast Medical Ima-
ging – Uptown, the Centre hospitalier universitaire de Montréal
(Montréal, Canada), the Centre d'Imagerie Moléculaire de Sherbrooke
of the Centre Hospitalier Universitaire de Sherbrooke (Sherbrooke,
Canada), Philips (Best, Netherlands), IRM Québec (Québec, Canada),
University of British Colombia (Vancouver, Canada), the Brain Imaging
Center of the Montreal Neurological Institute (Montréal, Canada), the
Hospital for Sick Children (Toronto, Canada), the Unité de Neuroima-
gerie Fonctionnelle du Centre de recherche de l'Institut universitaire en
gériatrie de Montréal (Montréal, Canada), the Centre Hospitalier Uni-
versitaire de Montréal (Montréal, Canada), the Brain Imaging Center of
the Institut universitaire en santé mentale Douglas (Montréal, Canada),
the Ottawa Civic Hospital (Ottawa, Canada), the Peter S. Allen MR
Research Center of the University of Alberta (Edmonton, Canada),
Queen's University (Kingston, Canada), the Robarts Research Institute
at the University of Western Ontario (London, Ontario), the Royal
University Hospital Radiology Department (Saskatoon, Canada), Sie-
mens (Erlangen, Germany), the St. Michael's Hospital (Toronto, Ca-
nada), the Radiology Department of Sunnybrook Hospital (Toronto,
Canada), and the York MRI Facility (Toronto, Canada).
The MEDICS Laboratory (CERVO Research Center, Québec, Canada)
was responsible for MRI data acquisition and analysis including co-
ordination, development and implementation of CDIP at each site; site
qualification; site quality control via the single volunteer scans; and on-
going quality assurance for the CCNA and CIMA-Q studies.
2.4. Image acquisition and processing
For the present study, 86 SIMON scans (nine on GE, 31 on Philips,
and 46 on Siemens) were acquired on 28 different 3-Tesla units (10
different models) over the course of eight years from 2009 to 2018
(Table 1). Twenty of these different scanners had more than one scan
and most were follow-up scans (64/86) with a mean scan interval of
238 days and a range between 0 and 873 days (GE: 448, 0–823; Philips:
251, 0–873; Siemens: 197, 0–595). The majority (69/86) of these scans
were acquired for the CCNA and CIMA-Q studies during development
and implementation of the protocol.
The CDIP (www.cdip-pcid.ca) has been previously described else-
where in detail (Duchesne et al., 2019). Briefly, the T1w acquisition
sequence is a sagittal 3D isotropic scan with high resolution (voxel
size= 1.0× 1.0×1.0mm3), an acceleration factor of 2 (Siemens: 3D
MP-RAGE-iPAT: 2; GE: 3D FAST-SPGR-ASSET 2.0; Philips: 3D TFE-Fast
Sense: 2). Parameters for the 3D T1w acquisition were inspired from
work done in the ADNI project (Jack Jr. et al., 2008), resulting in an
isotropic resolution and the use of accelerated imaging. One should
note that even if CDIP calls for precise parameter values, many acqui-
sitions displayed discrepancies with these targets. While this was cor-
rected for future acquisitions (the purpose of having a human phantom
being to test compliance and ensuring quality), it provided us with a
convenience sample of scans with different parameters. Reasons for
non-compliance included human initiative, and reduced precision due
to some scanner interfaces not allowing the precise entry and/or import
of set values.
Seventeen scans were acquired through other research projects,
including visits to manufacturers sites (see Table 1 for more details on
parameters). These images form a convenience sample, did not follow
any given protocol nor systematically assessed parameter variability,
but were acquired in the context of research studies and/or manu-
facturer visits, with an eye towards research studies. Thus, while these
protocols made different technical choices, all of them were deemed
suitable for research project purposes, and hence acceptable for our
study.
Brain volumes were extracted from each scan using recon-all pipe-
line of FreeSurfer 6.0 (http://freesurfer.net) with default parameters.
The total brain volume without the ventricles (brainsegvolnotvent)
from the aseg file was used.
2.5. Statistical analyses
To verify whether following CDIP parameters reduced morpho-
metric measures variability, we categorized scans based on their para-
meters (resolution, echo time (TE), repetition time (TR)) in a cumula-
tive fashion of being increasingly compliant with the CDIP protocol:
O. Potvin, et al. NeuroImage: Clinical 24 (2019) 101943
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CDIP (scans acquired with parameters within 1% of CDIP values);
CDIP±5% (all scans within 5% of CDIP values); CDIP± 10% (all scans
within 10% of CDIP values); and Any criteria (all scans). For GE and
Philips vendors, TR represents the inner loop gradient echo TR, whereas
for Siemens it represents the magnetization-prepared rapid gradient-
echo (MPRAGE) outer loop TR. Thus, we planned to analyze GE/Philips
and Siemens results separately. To compare variance across these ca-
tegories, p values between categories were calculated based on con-
fidence intervals (95%) computed from bootstrapping with 1000
random sampling with replacement. Moreover, to verify the effect of
protocol on morphometric measures, we used linear-mixed models with
parameter categories as a between factor (each image being within a
single category), age as covariate and scanner model as a random
factor.
All statistical analyses were conducted in Python using SciPy (Jones
et al., 2001) and StatsModels (Seabold and Perktold, 2010) modules.
3. Results
3.1. Parameter compliance
For unknown reasons, five images from Philips scanners had no TE
and TR values in the image headers, and these images were only used
for resolution analyses.
As mentioned earlier in Methods, because of the GE scanner inter-
face and human resources training at the visited sites, specific para-
meter values could not be easily transferred between machines. Thus,
even when sites intended to follow the CDIP protocol (9 out of 10
scans), no site matched the aimed CDIP TE value and only one site
matched the intended TR value. Further, due to automatic parameter
definition, all intended Philips CDIP scans were within 5% of expected
TE and TR values.
3.2. Impact of parameter compliance on morphometric variance value
Figs. 1, 2 and 3 show standard deviations for whole brain volumes
across categories for resolution, TE and TR parameters, respectively.
Resolution: For resolution, the parameter variability was not suffi-
cient to allow more than two categories, that is either meeting CDIP
values (1×1×1mm3) or not. When all vendors were grouped, the
CDIP resolution variance was not significantly lower than the non-CDIP
(p= .0746). Philips vendor results showed significant lower variance
(p= .0132) with the CDIP resolution value compared to other values
(note that Philips had the largest range of resolutions of all vendors).
TE: While variance increased in a stepwise fashion for TE across
categories, there was no statistically significant difference between
categories. The difference closest to reach significance was between
CDIP±1% and both CDIP± 10% (p= .0664) and “any criteria”
(p= .0603) categories. Results for GE images indicated significant
lower variance with the CDIP±5% compared to the “Any criteria”
(p= .0220) and CDIP± 10% (p= .0275) categories.
TR: Since there was no variance of TR for Siemens, analyses and
Fig. 3 concern only GE and Philips vendors, and thus this study focus on
inner-loop TR variability only. Compared to the CDIP±1% category,
higher variance was observed with the “Any criteria” category
(p= .0279). However, this difference was likely due to the GE vendor
results since no significant differences between categories were ob-
served for Philips (ps > 0.3888) while lower variance with the
CDIP±5% compared to the “Any criteria” (p= .0133) categories was
observed for GE.
For Siemens MRIs, while the interfaces allowed some parameters to
be entered directly, the system automatically calculated minimum
achievable TE values. Since we presented each unit with the same
parameter settings, this calculation showed very little variability
Fig. 1. Bar plot showing the median standard deviation of total brain volume
across vendors according to cumulative resolution criteria. Error bars denote
95% confidence intervals. White numbers indicate the number of scans meeting
each criterion.
Fig. 2. Bar plot showing the median standard deviation of total brain volume
across vendors according to cumulative echo time percentage discrepancy from
the CDIP criteria (GE 1%: 2.87–2.93ms, 5% 2.75–3.05 ms, 10%: 2.61–3.19ms;
Philips 1%: 2.75–3.33ms, 5% 2.83–3.47ms, 10%: 2.97–3.63ms; Siemens 1%:
2.95–3.01 ms, 5% 2.83–3.13ms, 10%: 2.68–3.28ms). Error bars denote 95%
confidence intervals. White numbers indicate the number of scans meeting each
criterion.
Fig. 3. Bar plot showing the median standard deviation of total brain volume
for GE and Philips vendors according to cumulative repetition time percentage
discrepancy from the CDIP criteria (GE 1%: 6.63–6.77ms, 5% 6.37–7.04ms,
10%: 6.03–7.37ms, Philips 1%: 7.23–7.37ms, 5%: 6.94–7.67ms, 10%:
6.57–8.03 ms). Error bars denote 95% confidence intervals. White numbers
indicate the number of scans meeting each criterion.
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between categories and all of them had similar resolution, TE, and TR
values.
3.3. Impact of parameter compliance on morphometric mean value
Figs. 4, 5 and 6 display boxplots showing the median and dispersion
of brain volumes across categories for the resolution, TE and TR para-
meters, respectively. Linear mixed models taking into account age and
scanner model, indicated that when all vendors were pooled together,
the mean brain volumes were not significantly different between CDIP
and non-CDIP resolution values (p= .0585). On the other hand, TE
CDIP±5% category had significantly larger brain volumes (1.9%,
p= .0252) compared to the ‘Any criteria’ category and CDIP± 1% was
also close to significance (1.5%, p= .0544). Similarly, for TR (GE and
Philips only), larger brain volumes CDIP±1% (1.4%, p= .0368) and
CDIP±5% (2.0%, p= .0047) compared to the ‘Any criteria’ category.
Finally, age had a significant effect in the resolution model (p= .0003),
but not in the TE (p= .2094) or TR (p= .6574) models, suggesting that
TE and TR variations were responsible for that age effect. Because of the
lack of parameters variability within each vendor leading to small
numbers for many categories, most separated linear mixed models were
not possible. Nonetheless, there was a significant effect of resolution for
Siemens images, with CDIP images having smaller brain volumes
(−2.4%, p= .0195).
4. Discussion
The harmonized Canadian Dementia Imaging Protocol has been
developed to suit the needs of several co-occurring Canadian studies
collecting data on brain changes across adulthood and
Fig. 4. Box plot showing the total brain volume across vendors according to resolution criteria. Boxes show the first and third quartiles with the line denoting the
median. Whiskers represent the lowest/highest datum still within 1.5 interquartile range (IQR) of the lower/higher quartile.
Fig. 5. Box plot showing the total brain volume across vendors according to echo time percentage discrepancy from the CDIP criteria (GE 1%: 2.87–2.93ms, 5%
2.75–3.05ms, 10%: 2.61–3.19 ms; Philips 1%: 2.75–3.33ms, 5% 2.83–3.47ms, 10%: 2.97–3.63ms; Siemens 1%: 2.95–3.01ms, 5% 2.83–3.13ms, 10%:
2.68–3.28ms). Boxes show the first and third quartiles with the line denoting the median. Whiskers represent the lowest/highest datum still within 1.5 interquartile
range (IQR) of the lower/higher quartile.
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neurodegeneration. In this study, we verified whether using the CDIP
was beneficial in lowering variability in gross brain size measurement
on a standard post-processing tool, without applying any specific image
pre/post processing. We used a substantial convenience dataset of a
single individual acquired on 10 scanner models across 86 different
sessions, which resulted in many of those not strictly adhering to the
CDIP-depicted parameter values.
First, using the CDIP resolution value (1×1×1mm) revealed that
compared to other resolution, the CDIP had lower brain volume var-
iance for Philips scanners. One possible factor in explaining the dif-
ference in reproducibility between vendors is the choices made during
post-acquisition reconstruction of images, for example the application
of smoothing/filtering (see Supplementary Fig. 1 for image examples of
each vendor). Customization at this processing level is usually not ac-
cessible to investigators. Second, brain volume variance appeared to
increase as deviation from the CDIP TE and TR parameters increased,
but this was significant only for GE scanners. Moreover, some mean
effects up to 2% were also observed, notably for the resolution para-
meter in Siemens scanners, with higher resolution leading to larger
volumes compared to the CDIP resolution.
Overall, these findings suggest that increasing non-adherence to a
standard protocol, at least for the tested parameters, correspondingly
increases morphological variability in brain measurements at a mag-
nitude on par with that of some pathologies of interest – either in a
transverse or longitudinal setting. They strengthen the argument for
ensuring compliance with a harmonized protocol for multi-centric
studies.
Further, the between-vendor offsets could feed into a next iteration
of the CDIP protocol, in order to change contrast and bring these
measures closer together.
4.1. Strengths
One strength of our study is the use of a unique dataset comprising
86 scans of a single individual across multiple scanner models, vendors,
and sites. To assess variability across sites in multi-centric studies, such
data are required and are relatively rare. The availability of such data
across sites and vendors is of paramount importance to the field of
image processing. As such, the CDIP group intends to make public all
MRI data acquired of SIMON, including all other CDIP contrasts (e.g.
T2*, PD/T2w, FLAIR, diffusion and resting state). There have been
other instances of similar data that have been acquired and distributed
to the community, notably: Brown et al. (2011), who tested 18 parti-
cipants to investigate sources of variation in the blood oxygen level-
dependent signal across four MRI sites; Friedman et al. (2008), who
used five participants to estimate the test-retest and between-site re-
liability of fMRI assessments across 10 MRI sites; Han et al. (2006), who
scanned 15 healthy older participants four times at three sites; Suckling
et al. (2012) who used 12 participants to carry out a test-retest cali-
bration experiment acquiring functional and structural MRI across three
MRI sites; and Suckling et al. (2014) who scanned six participants in
order to carry out calibration experiments at each of three MRI sites.
Comparatively, our study can contribute a dataset of a single subject,
scanned 86 times on 28 different units, which can be useful to answer a
number of methodological questions.
5. Limitations
The main limitation of our study is that the data originates from a
convenience sample, and therefore our acquisitions were not designed
to systematically study parameter variability. In fact, it was rather the
opposite; the implementation of the protocol was an attempt at re-
moving such variability. However, local variations, interface differ-
ences, and a few additional scans – outside of the CDIP project – al-
lowed for the comparisons being presented. In truth, variability mainly
differed between vendors due to interface design choices. Sequence
implementation choices for some vendors (e.g. Philips, GE) restrict the
number of parameters that can be fixed by the user, letting the system
automatically calculate values, whereas other manufacturers will allow
the complete specification – and therefore transfer – of parameter va-
lues from one scanner to another (e.g. Siemens), therefore increasing
conformity to a given protocol. One should note that Siemens
Healthcare platform is well represented in the Canadian research
landscape, it forms the bulk of the images under consideration while the
number of GE units is more limited in Canada, resulting in a lower
number of images (n=9). Therefore, conclusions regarding GE scan-
ners should be interpreted with caution. Most of our development took
place on Philips Medical System scanners, and hence we had the most
variability across resolution, TE and TR values for this platform and
thus, the strongest conclusions should be drawn for this subsample.
Fig. 6. Box plot showing the total brain volume for GE and Philips vendors according to repetition time percentage discrepancy from the CDIP criteria (GE 1%:
6.63–6.77ms, 5% 6.37–7.04ms, 10%: 6.03–7.37ms, Philips 1%: 7.23–7.37ms, 5%: 6.94–7.67ms, 10%: 6.57–8.03ms). Boxes show the first and third quartiles with
the line denoting the median. Whiskers represent the lowest/highest datum still within 1.5 interquartile range (IQR) of the lower/higher quartile.
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The ideal study would need to compare systematic variations of
CDIP parameters. However, such systematic parameters variations
would be hard to conduct in a single human subject, especially in a
multi-centric context since the same number of scans for each para-
meters combination would need to be evaluated for each site, yielding a
very high number of scans. However, using animals, this type of study
could be feasible. For example, a non-human primate could be anaes-
thetized and scanned with multiple systematic parameters variations,
which required to run the sequences multiple times and requires much
more time. However, even with this procedure, the logistic of traveling
with a live animal, especially in our case (across Canada), would pose
other challenges.
Moreover, since our objective was to assess whether the use of the
CDIP would be beneficial in lowering the variability in morphometric
measures of the brain before applying any specific image pre/post
processing, we used the FreeSurfer cross-sectional default pipeline to
process the images. Thus, we did not aim at maximizing the reliability
and other pipelines might yield different variability measurements.
Other steps can be done to further minimize variability across sites such
as image denoising, registration and distortion correction using geo-
metric phantoms; and in the case of longitudinal data, constrained re-
gistration. The use of different pipelines and the impact of these tech-
niques however, extended beyond the scope of this study.
Finally, when comparing images from different manufacturers, one
needs to be aware of differences in parameters that may at first pass
seem identical. For example, the definition of “sagittal acquisition” is
potentially ambiguous, given that there is no real ‘slice select’ direction
for acquisition but 2 phase-encoding directions instead, either of which
could represent the nominal ‘slice’ direction (and therefore define the
nominal orientation). This is important because it will influence the 3D
voxel point spread function, and therefore potentially affect the volu-
metric measurements reported in the manuscript, as well as de-
termining the direction of motion artifacts (e.g. from eye movement).
6. Conclusions
The results of the present study suggest that a harmonized protocol
like the CDIP may help to reduce variability in neuromorphometric
measures for multi-centric studies, but further studies with systematic
parameters variation are needed to draw firmer conclusions. The da-
taset used in this article is available on the International Neuroimaging
Data-Sharing initiative platform (INDI; http://fcon_1000.projects.nitrc.
org/indi/retro/SIMON.html).
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.nicl.2019.101943.
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